Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced that on December 1, 2025 it granted inducement restricted stock unit awards to two newly hired employees under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The awards total an aggregate of 2,200 restricted stock units, each representing the contingent right to one share of common stock. The RSUs vest in four equal annual installments beginning December 1, 2026, and vesting is conditioned on continued employment and the terms of each award agreement.

Argus Dec 3 session

+0.50% close to close Open Argus

Details

News Market Reaction – PCRX

In the Dec 3 session, PCRX gained 0.50%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details standard inducement grants totaling 2,200 restricted stock units to two ne...

Analysis

This announcement details standard inducement grants totaling 2,200 restricted stock units to two new employees under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years and are conditioned on continued employment. In the broader context, Pacira recently reported rising quarterly revenue of $179.5M and net income of $5.4M, while also managing patent litigation and activist interest. Investors may watch future filings, clinical updates, and insider activity to gauge how governance and strategy evolve.

Key Figures

Inducement RSUs: 2,200 shares Total revenue: $179.5M Net income: $5.4M +5 more

Inducement RSUs

2,200 shares

Granted to two new employees on Dec 1, 2025

Total revenue

$179.5M

Quarter ended Sep 30, 2025; vs $168.6M prior year

Net income

$5.4M

Quarter ended Sep 30, 2025; prior year included goodwill impairment loss

EXPAREL revenue

$139.9M

Net product sales in quarter ended Sep 30, 2025

Cash from operations

$108.3M

Nine months ended Sep 30, 2025

Cash & cash equivalents

$147.6M

Balance at Sep 30, 2025

Short-term investments

$98.7M

Balance at Sep 30, 2025

Convertible notes repaid

$202.5M

2025 notes repaid at maturity in Q3 2025

Historical Context

5 past events · Latest: Dec 03

5 events

1. Dec 03

   Inducement equity awards

   24h Move

   +0.5%

   Small RSU grants to two new employees under inducement plan.

2. Dec 02

   Clinical study update

   24h Move

   +1.6%

   12‑month pilot showed better pain and function with iovera° vs RFA.

3. Nov 26

   Patent litigation

   24h Move

   -1.0%

   EXPAREL® patent infringement lawsuits filed against two counterparties.

4. Nov 11

   Conference participation

   24h Move

   +4.5%

   Planned fireside chats at two major healthcare investor conferences.

5. Nov 10

   Activist involvement

   24h Move

   +4.5%

   Investor letter urging board to explore a potential sale of business.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

Nasdaq Listing Rule 5635(c)(4), restricted stock units

2 terms

Nasdaq Listing Rule 5635(c)(4) regulatory

"In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"Two employees received restricted stock units for an aggregate of 2,200 shares..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Two employees received restricted stock units for an aggregate of 2,200 shares of Pacira common stock. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on December 1, 2026.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com

Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pacira (PCRX) disclose about inducement awards on December 3, 2025?

Pacira disclosed it granted inducement restricted stock unit awards totaling 2,200 RSUs to two new employees on December 1, 2025 under its Inducement Plan.

How do the PCRX restricted stock units vest and when is the first vesting date?

The PCRX RSUs vest in four equal annual installments with the first vesting on December 1, 2026, subject to continued employment.

Were Pacira's inducement awards approved by shareholders for PCRX?

No; the People & Compensation Committee approved the awards under Nasdaq Rule 5635(c)(4) without stockholder approval.

How many employees received awards and how many shares do the PCRX RSUs represent?

Two employees received awards that together represent an aggregate of 2,200 shares of Pacira common stock.

What conditions must be met for PCRX RSU vesting to occur?

Vesting is conditioned on the employee's continued employment with Pacira and the terms of each award agreement.